Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
Clinical trial NCT04856189 · TERMINATED
Trial details
- NCT number
- NCT04856189
- Sponsor
- Mamta Parikh
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-08
- Primary completion
- 2024-01-04
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.